Biofrontera (0DOL) Price & Analysis

0 Followers

0DOL Stock Chart & Stats

€2.62

-€1.22(-50.97%)

At close: Apr 26 4:00 PM EDT

€2.62

-€1.22(-50.97%)

Day’s Range― - ―

52-Week Range€2.24 - €14.30

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€15.31M

Enterprise Value€11.99

Total Cash (Recent Filing)€3.08M

Total Debt (Recent Filing)€1.15M

Price to Earnings (P/E)―

Beta-0.51

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding6,076,862

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.99

Price to Sales (P/S)1.12

P/FCF Ratio-3.33

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Biofrontera News

Biofrontera Plans Move from Prime Standard to Frankfurt’s Scale Segment

Biofrontera ( ($DE:B8FK) ) has provided an update. Biofrontera AG’s management board, with supervisory board approval, has decided...

7d ago

Biofrontera AG Earnings Call Highlights Margin Pivot

Biofrontera AG (($DE:B8FK)) has held its Q1 earnings call. Read on for the main highlights of the call....

2M ago

Biofrontera Sets April 2026 Date for Release of 2025 Annual Report

Biofrontera ( ($DE:B8FK) ) has shared an update. Biofrontera AG has scheduled the publication of its annual report...

4M ago

Biofrontera Sets 2026 Guidance and Highlights Growing U.S. Earn-Out Income

The latest announcement is out from Biofrontera ( ($DE:B8FK) ). Biofrontera AG has issued financial guidance for 2026,...

5M ago

Biofrontera Raises 2025 EBITDA Outlook While Keeping Revenue Target

The latest update is out from Biofrontera ( ($DE:B8FK) ). Biofrontera AG has raised its EBITDA forecast for...

6M ago

Biofrontera AG Announces Significant Impairment Losses

Biofrontera ( ($DE:B8FK) ) has shared an announcement. Biofrontera AG has announced an expected impairment loss between €50...

10M ago

Biofrontera AG Announces New Financial Forecast for 2025

The latest update is out from Biofrontera ( ($DE:B8FK) ). Biofrontera AG, a company based in Leverkusen, Germany,...

1y ago

Biofrontera Completes Strategic Restructuring Agreement

An announcement from Biofrontera ( ($DE:B8FK) ) is now available. Biofrontera AG and Biofrontera Inc. have successfully met...

1y ago

Biofrontera AG Secures U.S. Operations Through Strategic Agreement with Biofrontera Inc.

Biofrontera ( ($DE:B8FK) ) has issued an update. Biofrontera AG has entered into a binding agreement with Biofrontera...

1y ago

Biofrontera AG Extends Payment Deferral Amid Strategic Negotiations

The latest update is out from Biofrontera ( ($DE:B8FK) ). Biofrontera AG has announced an extension of the...

1y ago

0DOL FAQ

What was Biofrontera AG’s price range in the past 12 months?

Biofrontera AG lowest share price was €2.24 and its highest was €14.30 in the past 12 months.

What is Biofrontera AG’s market cap?

Biofrontera AG’s market cap is €15.31M.

When is Biofrontera AG’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Biofrontera AG’s earnings last quarter?

Currently, no data Available

Is Biofrontera AG overvalued?

According to Wall Street analysts Biofrontera AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Biofrontera AG pay dividends?

Biofrontera AG pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on Biofrontera AG dividends here

What is Biofrontera AG’s EPS estimate?

Biofrontera AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Biofrontera AG have?

Biofrontera AG has 6,076,862 shares outstanding.

What happened to Biofrontera AG’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Biofrontera AG?

Currently, no hedge funds are holding shares in GB:0DOL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Biofrontera Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-20.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Biofrontera AG

Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the United States, and other global markets. Its primary products include Ameluz and the BF-RhodoLED lamp, which are utilized for treating mild to moderate actinic keratoses on the face and scalp, addressing field cancerization, and managing fatal squamous cell carcinoma. The company also supplies the RhodoLED XL lamp, engineered for treating multiple interspersed lesions, alongside Belixos, a cosmetic range developed for irritated and sensitive skin. Biofrontera AG maintains a licensing and supply agreement with Maruho Co., Ltd. Founded in 1997, the company's corporate headquarters are situated in Leverkusen, Germany.